P1426: WU‐NK‐101, AN ALLOGENEIC MEMORY NK CELL, FOR THE TREATMENT OF RELAPSE OR REFRACTORY (R/R) ACUTE MYELOID LEUKEMIA (AML)

MLA

Muth, J. J., et al. “P1426: Wu‐Nk‐101, an Allogeneic Memory Nk Cell, for the Treatment of Relapse or Refractory (R/R) Acute Myeloid Leukemia (Aml).” HemaSphere, vol. 6, June 2022, pp. 1309–10. EBSCOhost, https://doi.org/10.1097/01.HS9.0000848560.56093.16.

APA

Muth, J. J., Mathyer, M. E., Cruz, B., DuFour, C., Leedom, T., Hamil, A. S., Pouyanfard, S., Berrien, E. M., Luukkonen, L., Tran, M., Tumala, B., Pomper, N., Arthur, L., Foster, M., Gorrochategui, J., Comune Pennacchi, P., Primo, D., Ballesteros, J., Tolstikov, V., & Kiebish, M. A. (2022). P1426: Wu‐Nk‐101, an Allogeneic Memory Nk Cell, for the Treatment of Relapse or Refractory (R/R) Acute Myeloid Leukemia (Aml). HemaSphere, 6, 1309–1310. https://doi.org/10.1097/01.HS9.0000848560.56093.16

Chicago

Muth, J. J., M. E. Mathyer, B. Cruz, C. DuFour, T. Leedom, A. S. Hamil, S. Pouyanfard, et al. 2022. “P1426: Wu‐Nk‐101, an Allogeneic Memory Nk Cell, for the Treatment of Relapse or Refractory (R/R) Acute Myeloid Leukemia (Aml).” HemaSphere 6 (June): 1309–10. doi:10.1097/01.HS9.0000848560.56093.16.